| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000043492 |
| Receipt No. | R000049665 |
| Scientific Title | A verification study for the effects of consumption of the test food on the improvement of brain fatigue: A randomized, double-blind, placebo-controlled, parallel-group comparison trial |
| Date of disclosure of the study information | 2021/03/02 |
| Last modified on | 2022/08/05 (Ver. 5) |
| Basic information | ||
| Public title | A verification study for the improvement of brain fatigue | |
| Acronym | A verification study for the effects of consumption of the test food on the improvement of brain fatigue | |
| Scientific Title | A verification study for the effects of consumption of the test food on the improvement of brain fatigue: A randomized, double-blind, placebo-controlled, parallel-group comparison trial | |
| Scientific Title:Acronym | A verification study for the effects of consumption of the test food on the improvement of brain fatigue | |
| Region |
|
|
| Condition | |||
| Condition | Healthy Japanese subjects | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To verify the effects of the test food on the improvement of brain fatigue |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 1. The measured values of Visual Analogue Scale (VAS) of fatigue at before and after the fatigue load of four weeks after the start of test food consumption |
| Key secondary outcomes | 1. The measured values of VAS of fatigue at before and after the fatigue load of two weeks after the start of test food consumption (2w)
2. The amount of changes of VAS of fatigue at before and after the fatigue load from screening (before consumption; Scr) to 2w and four weeks after the start of test food consumption (4w) 3. The measured values of VAS of fatigue at before the fatigue load and after the fatigue load at 2w and 4w, and the amount of changes from Scr to 2w and 4w 4. The measured values of standardized score in each cognitive domain by Cognitrax at 2w and 4w, and the amount of changes from Scr to 2w and 4w 5. The measured values of flicker value (average of both eyes, dominant eye, and non-dominant eye), and VAS {sharp mind, concentration, thinking ability, brain (mental) fatigue, motivation (commitment), stress, frustration, stiff shoulder (fatigue in the shoulders), malaise (languor), and eye fatigue} at before, after, and before and after the fatigue load at 2w and 4w, and the amount of changes from Scr to 2w and 4w 6. The measured values of "My head doesn't feel clear when I wake up from sleep," "My head doesn't feel clear in the evening," "My sleep quality is not good," "I am concerned about my body odor," and "I am concerned about odor in my mouth" at 2w and 4w * The value of "before and after the fatigue load" is defined as value subtracted after the fatigue load from before the fatigue load. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duration: Four weeks
Test food: Tablet containing garlic extract Administration: Take two tablets within 30 minutes after breakfast. * Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day. |
|
| Interventions/Control_2 | Duration: Four weeks
Test food: Placebo Administration: Take two tablets within 30 minutes after breakfast. * Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day. |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Japanese
2. Male or female 3. Subjects aged 20 or more 4. Healthy subjects 5. Subjects who are judged as eligible to participate in the study by the physician 6. Subjects who have a relatively big difference in VAS of fatigue between before and after the fatigue load |
|||
| Key exclusion criteria | 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction
2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Subjects currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional food/beverage in daily use 5. Subjects who take supplements related to improving cognitive functions, such as garlic extract, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), ginkgo leaf extract, astaxanthin, and gamma-aminobutyric acid (GABA) in daily 6. Subjects who use tools, games, devices, and application related to improving cognitive functions such as Shogi, Go, and puzzle or game of brain training in daily 7. Subjects currently taking medicines (include herbal medicines) and supplements 8. Subjects who are allergic to medicines and/or the test food related products 9. Subjects who are pregnant, breast-feeding, and planning to become pregnant 10. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial 11. Subjects who are judged as ineligible to participate in the study by the physician |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Medical Corporation Seishinkai, Takara Clinic | ||||||
| Division name | Director | ||||||
| Zip code | 141-0022 | ||||||
| Address | 9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan. | ||||||
| TEL | 03-5793-3623 | ||||||
| t-takara@takara-clinic.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | ORTHOMEDICO Inc. | ||||||
| Division name | R&D Department | ||||||
| Zip code | 112-0002 | ||||||
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. | ||||||
| TEL | 03-3818-0610 | ||||||
| Homepage URL | |||||||
| nao@orthomedico.jp | |||||||
| Sponsor | |
| Institute | ORTHOMEDICO Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Bizen Chemical Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Medical Corporation Seishinkai, Takara Clinic
Nerima Medical Association, Minami-machi Clinic |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | the ethical committee of the Takara Clinic, Medical Corporation Seishinkai |
| Address | 9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan. |
| Tel | 03-5793-3623 |
| IRB@takara-clinic.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan) 南町医院 (東京都) Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 22 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049665 |